logo

ABOS

Acumen·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

ABOS fundamentals

Acumen (ABOS) released its earnings on Nov 12, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.44 (YoY +12.00%), beat estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.44
+12.00%
Report date
Nov 12, 2025
ABOS Earnings Call Summary for Q3,2025
  • Clinical Momentum: ALTITUDE-AD enrollment complete; EBD program nonhuman primate studies Q1 2026.
  • Financial Strength: $136M cash; cost-efficient operations.
  • Strategic Differentiation: Sabirnetug's oligomer selectivity and JCR's TfR tech for enhanced CNS delivery.
  • Competitive Watch: Tracking Novo's GLP-1 trials; potential AD therapy combinations.
  • Safety Profile: No ARIA risks; JCR's anemia mitigation strategy.
  • Biomarker Focus: Synaptic health markers (neurogranin, VAMP2) for AD progression tracking.
EPS
Revenue

Revenue & Expenses

Key Indicators

Acumen (ABOS) key financial stats and ratios, covering profitability, financial health, and leverage.
Acumen (ABOS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Acumen (ABOS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Acumen (ABOS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Acumen (ABOS) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Acumen (ABOS) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield